Introduction: Who Should Undergo Diagnostic Testing

Hepatic angiosarcoma is an uncommon type of cancer that develops in the cells lining the blood vessels within the liver. Because it represents only about 0.1% to 2% of all primary liver cancers, many people may never have heard of it until they or a loved one face a diagnosis. This rarity also means that doctors need to maintain a high level of awareness when certain symptoms or risk factors appear.^[1]

People who should consider seeking medical evaluation include those experiencing persistent upper abdominal pain, unexplained weight loss, yellowing of the skin and eyes (a condition called jaundice), unusual fatigue, or swelling in the belly area. These symptoms are not specific to hepatic angiosarcoma and can occur with many other conditions, but they warrant medical attention nonetheless. Some individuals may have no symptoms at all in the early stages, and the tumor might be discovered accidentally during imaging tests performed for other reasons.^[2]

Certain groups face higher risk and may benefit from increased vigilance. These include older adults, particularly men in their 60s and 70s, as hepatic angiosarcoma most commonly affects this demographic. People with a history of exposure to industrial chemicals such as vinyl chloride, arsenic, or a substance called thorotrast (once used as a medical contrast agent) should be especially attentive. Interestingly, the disease can take 10 to 40 years to develop after such exposures, meaning symptoms may appear long after the actual contact occurred.^[1]

Those who work or have worked in industries involving the production of polyvinyl chloride plastics, pesticide manufacturing, or metal processing may have been exposed to harmful chemicals linked to this cancer. Additionally, individuals who used androgenic steroids for extended periods or received certain types of radiation therapy may also carry increased risk. While most cases (about 75%) occur without any identifiable cause, knowing your exposure history can help doctors decide whether further testing is appropriate.^[4]

Classic Diagnostic Methods

Diagnosing hepatic angiosarcoma presents significant challenges because its appearance on tests often resembles other, more common liver tumors. The diagnosis typically begins when a patient visits their doctor with concerning symptoms or when a liver abnormality is noticed during routine imaging. The journey to a confirmed diagnosis involves multiple steps and different types of examinations.

Medical History and Physical Examination

The diagnostic process starts with a thorough medical history. Your doctor will ask detailed questions about your symptoms, including when they started, how severe they are, and whether anything makes them better or worse. Questions about your work history, particularly any exposure to industrial chemicals, are especially important. Your doctor will also want to know about any medications you’ve taken, including steroids or oral contraceptives, and whether you’ve received radiation therapy in the past.^[1]

During the physical examination, the doctor will carefully check your abdomen for tenderness, swelling, or an enlarged liver (a condition called hepatomegaly). They will also look for signs of jaundice by examining the whites of your eyes and your skin. Fluid buildup in the abdomen, known as ascites, may be detected by tapping on the belly and listening for specific sounds. Sometimes, however, the physical exam reveals nothing unusual, especially in early-stage disease.^[4]

Blood Tests and Laboratory Investigations

Blood work forms an essential part of the initial evaluation. These tests help doctors understand how well your liver is functioning and whether there are signs of disease. Common blood tests include liver function tests, which measure enzymes and proteins that indicate liver health. Interestingly, liver function often remains normal until the very late stages of hepatic angiosarcoma, which can delay diagnosis.^[4]

Other blood tests check for tumor markers, which are substances sometimes produced by cancer cells. In hepatic angiosarcoma, standard liver cancer markers like alpha-fetoprotein (AFP) usually remain within normal ranges, which helps distinguish this cancer from more common liver cancers like hepatocellular carcinoma. Blood counts may reveal anemia (low red blood cell count) or thrombocytopenia (low platelet count), which occur in some patients. Coagulation studies assess how well your blood clots, as some individuals develop bleeding problems.^[6]

Imaging Studies

Medical imaging plays a central role in detecting and evaluating hepatic angiosarcoma, though no single imaging technique can definitively diagnose the disease. Ultrasound is often the first imaging test performed because it’s widely available, relatively inexpensive, and doesn’t involve radiation exposure. During an ultrasound, sound waves create images of the liver, potentially revealing masses or abnormal areas. However, ultrasound alone cannot distinguish hepatic angiosarcoma from other liver tumors.^[1]

Computed tomography (CT) scans provide more detailed images by taking multiple X-ray pictures from different angles and combining them into cross-sectional views. When contrast dye is injected into a vein before the scan, it helps highlight blood vessels and tumors. In hepatic angiosarcoma, CT scans may show multiple masses throughout the liver with areas of varying density. The tumors often contain regions of bleeding or dead tissue, creating a characteristic but not unique appearance. Sometimes, CT scans reveal active bleeding from a ruptured tumor, which appears as fluid leaking into the abdomen.^[6]

Magnetic resonance imaging (MRI) offers another way to examine the liver using powerful magnets and radio waves instead of X-rays. MRI provides excellent detail of soft tissues and can show the internal structure of liver tumors. Like CT scans, MRI uses contrast agents to enhance visibility. The combination of different imaging techniques helps doctors better characterize suspicious areas and plan for biopsy or treatment.^[2]

Biopsy: Confirming the Diagnosis

Despite all the imaging studies available, the only way to definitively confirm hepatic angiosarcoma is through a biopsy—removing a small piece of the suspicious tissue for examination under a microscope. This step is crucial because hepatic angiosarcoma looks similar to other liver tumors on imaging, and treatment approaches differ significantly depending on the exact type of cancer.^[7]

Biopsies can be performed in different ways. The most common method is a needle biopsy, where a thin needle is inserted through the skin and into the liver mass under guidance from ultrasound or CT imaging. This procedure, called a percutaneous biopsy, is relatively quick and can often be done with local anesthesia. However, there are risks involved, particularly because hepatic angiosarcoma tumors contain many blood vessels and can bleed easily. In some cases, bleeding can be severe and life-threatening.^[4]

When needle biopsy isn’t safe or doesn’t provide enough tissue, a surgical biopsy may be necessary. This involves making an incision and directly obtaining a tissue sample, sometimes during an operation to remove the tumor. The tissue sample is then sent to a pathologist, a doctor who specializes in diagnosing diseases by examining tissues. The pathologist looks for specific features of angiosarcoma cells, including their appearance and how they’re arranged.

Special Staining and Tumor Markers

Examining biopsy tissue under a microscope involves more than just looking at the cells. Pathologists use special staining techniques that help identify specific proteins on the surface of cancer cells. For hepatic angiosarcoma, a protein marker called CD31 is considered the most reliable indicator. When cancer cells test positive for CD31, it strongly suggests the tumor originated from blood vessel lining cells, which is characteristic of angiosarcoma.^[4]

Other markers that pathologists may check include Factor VIII-related antigen and CD34, which are also associated with blood vessel cells. Using a combination of these markers increases diagnostic accuracy. The pathologist’s report, which describes the tissue findings and marker results, provides the final confirmation of hepatic angiosarcoma.^[1]

Differential Diagnosis: Distinguishing from Other Conditions

One of the most challenging aspects of diagnosing hepatic angiosarcoma is distinguishing it from other liver conditions. The most common confusion is with hepatocellular carcinoma, the most prevalent type of primary liver cancer. Both can cause similar symptoms and may look alike on imaging. However, hepatocellular carcinoma typically occurs in people with chronic liver disease or cirrhosis, and blood tests usually show elevated alpha-fetoprotein levels, which doesn’t happen with angiosarcoma.^[7]

Another condition that can mimic hepatic angiosarcoma is hemangioma, a benign (non-cancerous) collection of blood vessels in the liver. Hemangiomas are actually quite common and usually cause no symptoms or problems. Imaging studies can sometimes distinguish between hemangioma and angiosarcoma based on patterns of blood flow and contrast enhancement, but biopsy may still be needed for certainty.^[4]

Other liver cancers, such as cholangiocarcinoma (bile duct cancer) or metastatic tumors that have spread to the liver from other body parts, may also need to be ruled out. Each of these conditions requires different treatment approaches, making accurate diagnosis essential for proper care.^[2]

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments for various diseases, including rare cancers like hepatic angiosarcoma. Because these trials must ensure patient safety and produce reliable results, they have specific requirements that patients must meet before enrolling. These requirements, called eligibility criteria, typically include particular diagnostic tests and findings.

Pathological Confirmation

Nearly all clinical trials for hepatic angiosarcoma require pathological confirmation of the diagnosis through biopsy. Trial organizers need documented proof that a patient truly has angiosarcoma rather than another type of liver cancer. This usually means having biopsy tissue examined by a pathologist who confirms the presence of malignant cells with characteristics of angiosarcoma, including positive staining for markers like CD31.^[9]

Some trials may require that the biopsy be reviewed by their own pathologists or at a central laboratory to ensure consistency in diagnosis across all study participants. This process, called central pathology review, helps guarantee that everyone in the trial has the same disease, making the results more reliable and meaningful.

Staging and Disease Extent

Clinical trials often specify which disease stages they will accept. Staging describes how far the cancer has spread and typically uses a system that considers tumor size, number of tumors, involvement of lymph nodes, and whether the cancer has metastasized (spread) to distant organs. The TNM staging system is commonly used, where T stands for tumor characteristics, N represents lymph node involvement, and M indicates metastasis.^[2]

To determine stage, patients undergo comprehensive imaging studies. These typically include CT scans of the chest, abdomen, and pelvis to look for tumors in the liver and check whether cancer has spread to the lungs, lymph nodes, or other organs. MRI may also be performed to provide additional detail about the liver tumors. PET scans, which show areas of high metabolic activity that might indicate cancer, are sometimes used as well.

Performance Status Assessment

Clinical trials assess how well patients can carry out their daily activities using standardized scales called performance status scores. The most common scales are the Eastern Cooperative Oncology Group (ECOG) scale and the Karnofsky Performance Status scale. These scores range from fully active (able to carry on all pre-disease activities) to completely disabled (confined to bed or chair).^[9]

Most trials require patients to have a good performance status, meaning they can take care of themselves and are up and about more than half the day. This requirement helps ensure that patients are strong enough to tolerate the experimental treatment and complete the study. Performance status is assessed through questionnaires and physician evaluation during screening visits.

Organ Function Testing

Because treatments can affect various organs, clinical trials typically require baseline testing to ensure patients have adequate organ function before starting therapy. For hepatic angiosarcoma trials, this commonly includes detailed liver function tests measuring enzymes, bilirubin (a substance processed by the liver), and proteins made by the liver. Interestingly, many hepatic angiosarcoma patients maintain relatively normal liver function even with extensive disease, but trials still need to document baseline values.^[4]

Kidney function tests, including blood urea nitrogen (BUN) and creatinine levels, assess how well the kidneys are working. Heart function is evaluated through electrocardiograms (ECG or EKG), which record the heart’s electrical activity, and sometimes echocardiograms, which use sound waves to create moving images of the heart. Blood counts check for adequate numbers of red blood cells, white blood cells, and platelets, as many cancer treatments affect these cells.^[9]

Molecular and Genetic Testing

Some modern clinical trials focus on targeted therapies that work on specific genetic changes within cancer cells. These trials may require molecular testing of tumor tissue to identify particular mutations or alterations. For hepatic angiosarcoma, research has found certain genetic changes in some cases, such as TP53 mutations in tumors associated with vinyl chloride exposure and KRAS-2 mutations in those linked to thorotrast exposure.^[1]

Molecular testing involves analyzing DNA or RNA from biopsy samples using specialized laboratory techniques. Results help determine whether a patient’s tumor has the specific characteristics targeted by the experimental treatment being studied. Not all hepatic angiosarcoma trials require molecular testing, but as our understanding of the disease’s biology grows, such testing may become more common.

Quality of Life Assessments

Many clinical trials include evaluations of patients’ quality of life using standardized questionnaires. These assessments measure physical symptoms, emotional well-being, social functioning, and overall life satisfaction. Patients complete questionnaires at the beginning of the trial and at regular intervals throughout treatment. This information helps researchers understand not just whether a treatment extends survival, but also how it affects patients’ day-to-day experiences and well-being.^[9]

Exclusion Criteria and Additional Testing

Clinical trials also specify conditions or situations that would exclude someone from participating. Common exclusions include other active cancers, serious medical conditions that might interfere with treatment safety, previous treatment with similar drugs, or pregnancy. Additional diagnostic tests may be required to rule out these exclusions, such as pregnancy tests for women of childbearing age or additional imaging to confirm no other cancers are present.

The specific diagnostic requirements vary considerably between different clinical trials. Some trials study first-line treatments for newly diagnosed patients who haven’t received any prior therapy, while others focus on patients whose disease has progressed despite previous treatments. Each trial has its own particular criteria designed to answer specific research questions while keeping participants as safe as possible.^[9]